Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depigoid Grass Mix rush immunotherapy in grass pollen allergic rhinitis
2006-005269-20Phase 3Completed
- Sponsor
- LETI Pharma
- Start
- Nov 2006
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC) comparing Depigoid Grass Mix with Placebo (2 arms). Primary endpoints: Primary efficacy endpoint and Additional efficacy endpoint. Started Nov 2006; status: completed.
02
Drugs
Depigoid Grass Mix
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2006-005269-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005269-20.